Aarey Drugs & Pharmaceuticals (NSE:AAREYDRUGS) ROCE %: 5.76% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AAREYDRUGS Aarey Drugs & Pharmaceuticals Ltd NSE:AAREYDRUGS
62 GF Score
Price ₹98.89
GF Value ₹52.85
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Aarey Drugs & Pharmaceuticals ROCE %?

Aarey Drugs & Pharmaceuticals NSE:AAREYDRUGS +3.32% 62 ROCE % is 5.76% as of Jun. 2026. GuruFocus rates NSE:AAREYDRUGS with a GF Score™ of 62/100 and a GF Value™ of ₹52.85 (Significantly Overvalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aarey Drugs & Pharmaceuticals's annualized ROCE % for the quarter that ended in Jun. 2026 was 5.76%.

Aarey Drugs & Pharmaceuticals  (NSE:AAREYDRUGS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aarey Drugs & Pharmaceuticals ROCE % Related Terms

Aarey Drugs & Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Aarey Drugs & Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarey Drugs & Pharmaceuticals ROCE % Chart

Aarey Drugs & Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.83 7.14 7.43 7.74 7.10

Aarey Drugs & Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.82 7.26 4.88 8.06 5.76
NSE:AAREYDRUGS
62GF Score
Aarey Drugs & Pharmaceuticals Ltd NSE:AAREYDRUGS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarey Drugs & Pharmaceuticals ROCE % Calculation

Aarey Drugs & Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=104.16/( ( (2905.92 - 1492.061) + (2972.467 - 1450.766) )/ 2 )
=104.16/( (1413.859+1521.701)/ 2 )
=104.16/1467.78
=7.10 %

Aarey Drugs & Pharmaceuticals's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=87.6/( ( (2972.467 - 1450.766) + (0 - 0) )/ 1 )
=87.6/( ( 1521.701 + 0 )/ 1 )
=87.6/1521.701
=5.76 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.76% mean?
Aarey Drugs & Pharmaceuticals (NSE:AAREYDRUGS) has a ROCE % of 5.76% as of Jun. 2026.
Is Aarey Drugs & Pharmaceuticals' ROCE % too high?
Aarey Drugs & Pharmaceuticals' current ROCE % is 5.76%. The Drug Manufacturers industry median ROCE % is 6.55. Aarey Drugs & Pharmaceuticals' value of 5.76% is 12.1% below this industry median. Overall, Aarey Drugs & Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aarey Drugs & Pharmaceuticals' ROCE % compare to ZTS?
Aarey Drugs & Pharmaceuticals' ROCE % of 5.76% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 6.55. Aarey Drugs & Pharmaceuticals' value of 5.76% is 12.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 6.55, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarey Drugs & Pharmaceuticals's current ROCE % of 5.76% is 12.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 6.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarey Drugs & Pharmaceuticals's current ROCE % is 5.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarey Drugs & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals (NSE:AAREYDRUGS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹52.85, compared to a current price of ₹98.89 — trading 87.1% above its estimated fair value. The current ROCE % is 5.76% and 12.1% below the Drug Manufacturers industry median of 6.55. Aarey Drugs & Pharmaceuticals' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Aarey Drugs & Pharmaceuticals (NSE:AAREYDRUGS), the current ROCE % is 5.76% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarey Drugs & Pharmaceuticals (NSE:AAREYDRUGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals stock appears to be overvalued. The current stock price of ₹98.89 is trading 87.1% above its estimated GF Value™ of ₹52.85. GuruFocus considers Aarey Drugs & Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:AAREYDRUGS:

  • ROCE %: 5.76%
  • GF Value™: ₹52.85 vs. price of ₹98.89 (87.1% above fair value)
  • GF Score™: 62/100 with 8 warning signs
  • Industry Position: 12.1% below the Drug Manufacturers median

No single metric tells the full story. See the NSE:AAREYDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarey Drugs & Pharmaceuticals Business Description

Other Exchanges 524412:India
Address 340/348, Narshi Natha Street, 107, Sahakar Bhavan, Masjid Bunder, Mumbai, MH, IND, 400 009
Aarey Drugs & Pharmaceuticals Ltd is engaged in bulk drug manufacturing and offers products for industrial applications. The company manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals. It is also involved in the trading of industrial solvents and chemicals. The products offered by the company include N-Methyl urea, Dimethyl urea, Mefenamic acid, Metformin, Doxaphylline, and BMD among others. The company principally carries out its business operations in India.
62GF Score

Get the complete analysis for NSE:AAREYDRUGS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹98.89
Price
₹52.85
GF Value